Douglas W. McMillin

3.6k total citations
57 papers, 2.1k citations indexed

About

Douglas W. McMillin is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Douglas W. McMillin has authored 57 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Molecular Biology, 27 papers in Hematology and 21 papers in Oncology. Recurrent topics in Douglas W. McMillin's work include Multiple Myeloma Research and Treatments (23 papers), Ubiquitin and proteasome pathways (11 papers) and Cancer-related Molecular Pathways (8 papers). Douglas W. McMillin is often cited by papers focused on Multiple Myeloma Research and Treatments (23 papers), Ubiquitin and proteasome pathways (11 papers) and Cancer-related Molecular Pathways (8 papers). Douglas W. McMillin collaborates with scholars based in United States, Greece and Switzerland. Douglas W. McMillin's co-authors include Constantine S. Mitsiades, Joseph Negri, Kenneth C. Anderson, Paul G. Richardson, Nicholas Mitsiades, Jake Delmore, Nikhil C. Munshi, Steffen Klippel, Teru Hideshima and Andrew L. Kung and has published in prestigious journals such as Journal of Clinical Investigation, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Douglas W. McMillin

56 papers receiving 2.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Douglas W. McMillin United States 25 1.2k 837 642 329 263 57 2.1k
Erwin R. Boghaert United States 26 1.2k 1.0× 1.0k 1.3× 370 0.6× 245 0.7× 196 0.7× 58 2.5k
Patrick A. Mayes United States 17 1.4k 1.1× 1.2k 1.4× 381 0.6× 586 1.8× 521 2.0× 31 2.5k
Sonia Vallet United States 31 1.8k 1.5× 1.5k 1.8× 1.4k 2.1× 345 1.0× 239 0.9× 104 3.3k
J I Johnson United States 7 1.3k 1.1× 853 1.0× 359 0.6× 138 0.4× 316 1.2× 7 2.0k
Evelyn McKeegan United States 19 1.3k 1.1× 771 0.9× 296 0.5× 238 0.7× 234 0.9× 42 2.1k
Simona Ronzoni Italy 17 2.2k 1.8× 1.3k 1.6× 401 0.6× 328 1.0× 659 2.5× 29 3.2k
Jiro Kikuchi Japan 27 1.5k 1.2× 594 0.7× 685 1.1× 352 1.1× 209 0.8× 89 2.2k
Rui-Yu Wang United States 14 964 0.8× 669 0.8× 472 0.7× 336 1.0× 262 1.0× 20 1.7k
Meike Vogler Germany 26 2.1k 1.8× 769 0.9× 290 0.5× 563 1.7× 362 1.4× 59 2.9k
Stephanie Grabow Australia 19 1.6k 1.3× 590 0.7× 196 0.3× 595 1.8× 272 1.0× 33 2.2k

Countries citing papers authored by Douglas W. McMillin

Since Specialization
Citations

This map shows the geographic impact of Douglas W. McMillin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas W. McMillin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas W. McMillin more than expected).

Fields of papers citing papers by Douglas W. McMillin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas W. McMillin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas W. McMillin. The network helps show where Douglas W. McMillin may publish in the future.

Co-authorship network of co-authors of Douglas W. McMillin

This figure shows the co-authorship network connecting the top 25 collaborators of Douglas W. McMillin. A scholar is included among the top collaborators of Douglas W. McMillin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Douglas W. McMillin. Douglas W. McMillin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Donk, Niels W.C.J. van de, Monique C. Minnema, Julie H. Huang, et al.. (2013). Accessory Cells of the Microenvironment Protect Multiple Myeloma from T-Cell Cytotoxicity through Cell Adhesion-Mediated Immune Resistance. Clinical Cancer Research. 19(20). 5591–5601. 51 indexed citations
2.
Rickles, Richard J., Winnie F. Tam, Thomas P. Giordano, et al.. (2012). Adenosine A2A and Beta-2 Adrenergic Receptor Agonists: Novel Selective and Synergistic Multiple Myeloma Targets Discovered through Systematic Combination Screening. Molecular Cancer Therapeutics. 11(7). 1432–1442. 13 indexed citations
3.
McMillin, Douglas W., Hannah M. Jacobs, Jake Delmore, et al.. (2012). Molecular and Cellular Effects of NEDD8-Activating Enzyme Inhibition in Myeloma. Molecular Cancer Therapeutics. 11(4). 942–951. 46 indexed citations
4.
McMillin, Douglas W. & Constantine S. Mitsiades. (2012). High-throughput approaches to discover novel immunomodulatory agents for cancer. OncoImmunology. 1(8). 1406–1408. 6 indexed citations
5.
McMillin, Douglas W., Jake Delmore, Joseph Negri, et al.. (2012). Compartment-specific bioluminescence imaging platform for the high-throughput evaluation of antitumor immune function. Blood. 119(15). e131–e138. 24 indexed citations
6.
Jakubı́ková, Jana, David Cervi, Melissa Ooi, et al.. (2011). Anti-tumor activity and signaling events triggered by the isothiocyanates, sulforaphane and phenethyl isothiocyanate, in multiple myeloma. Haematologica. 96(8). 1170–1179. 63 indexed citations
7.
Donk, Niels W.C.J. van de, Henk M. Lokhorst, Maarten E. Emmelot, et al.. (2011). Proteasome Inhibitors Sensitize Myeloma Cells to T Cell-Mediated Killing. Blood. 118(21). 1838–1838. 2 indexed citations
8.
McMillin, Douglas W., Jake Delmore, Ellen Weisberg, et al.. (2010). Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nature Medicine. 16(4). 483–489. 236 indexed citations
9.
Ooi, Melissa, Patrick Hayden, Vassiliki Kotoula, et al.. (2009). Interactions of the Hdm2/p53 and Proteasome Pathways May Enhance the Antitumor Activity of Bortezomib. Clinical Cancer Research. 15(23). 7153–7160. 53 indexed citations
10.
McMillin, Douglas W., Melissa Ooi, Jake Delmore, et al.. (2009). Antimyeloma Activity of the Orally Bioavailable Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235. Cancer Research. 69(14). 5835–5842. 105 indexed citations
11.
Li, Jianming, Lauren T. Southerland, Ying Lu, et al.. (2009). Activation, Immune Polarization, and Graft-versus-Leukemia Activity of Donor T-cells are Regulated by Specific Subsets of Donor Bone Marrow Antigen-Presenting Cells in Allogeneic Hematopoietic Stem Cell Transplantation. Journal of Immunological Methods. 183(12). 7799–7809. 1 indexed citations
12.
13.
Weisberg, Ellen, Renee D. Wright, Douglas W. McMillin, et al.. (2008). Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells. Molecular Cancer Therapeutics. 7(5). 1121–1129. 60 indexed citations
14.
Weisberg, Ellen, Andrew L. Kung, Renee D. Wright, et al.. (2007). Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells. Molecular Cancer Therapeutics. 6(7). 1951–1961. 66 indexed citations
15.
Mitsiades, Constantine S., Joseph Negri, Ciaran J. McMullan, et al.. (2007). Targeting BRAFV600E in thyroid carcinoma: therapeutic implications. Molecular Cancer Therapeutics. 6(3). 1070–1078. 43 indexed citations
16.
Negri, Joseph, Douglas W. McMillin, Nicholas Mitsiades, et al.. (2006). Anti-Myeloma Activity of the Small-Molecule Aurora Kinase Inhibitor VE465.. Blood. 108(11). 3468–3468. 2 indexed citations
17.
Raab, Marc S., Jing Zhang, Douglas W. McMillin, et al.. (2006). Targeting PKC in Multiple Myeloma: In Vitro and In Vivo Effects of the Novel, Orally Available Small-Molecule Inhibitor Enzastaurin (LY317615.HCl).. Blood. 108(11). 3466–3466. 5 indexed citations
18.
Mitsiades, Constantine S., Vassiliki Poulaki, Galinos Fanourakis, et al.. (2006). Fas Signaling in Thyroid Carcinomas Is Diverted from Apoptosis to Proliferation. Clinical Cancer Research. 12(12). 3705–3712. 51 indexed citations
19.
20.
Xiao, Xiang, et al.. (1998). VLA-5 is expressed by mouse and human long-term repopulating hematopoietic cells and mediates adhesion to extracellular matrix protein fibronectin.. Journal of Clinical Investigation. 102(5). 1051–1061. 132 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Erwin R. Boghaert Breakdown of academic impact, for papers by Patrick A. Mayes Breakdown of academic impact, for papers by Sonia Vallet Breakdown of academic impact, for papers by J I Johnson Breakdown of academic impact, for papers by Evelyn McKeegan Breakdown of academic impact, for papers by Simona Ronzoni Breakdown of academic impact, for papers by Jiro Kikuchi Breakdown of academic impact, for papers by Rui-Yu Wang Breakdown of academic impact, for papers by Meike Vogler Breakdown of academic impact, for papers by Stephanie Grabow
Rankless by CCL
2026